MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY Russian patent published in 2022 - IPC C07K16/10 A61K39/395 A61K39/215 A61P31/14 

FIELD: biotechnology.

SUBSTANCE: inventions group relates to the field of biotechnology, immunology and virology. Means and methods for the treatment and emergency prevention of diseases caused by various strains of the severe acute respiratory syndrome virus SARS-CoV-2 are described. An agent has been created that contains a recombinant antibody having a CDR1 represented by the amino acid sequence of SEQ ID NO:1, a CDR2 represented by the amino acid sequence of SEQ ID NO:2, a CDR3 represented by the amino acid sequence of SEQ ID NO:3, as well as an Fc fragment of human IgG1 and a humanized monoclonal antibody having a light chain CDR1 represented by SEQ ID NO:4, light chain CDR2 represented by SEQ ID NO:5, light chain CDR3 represented by SEQ ID NO:6, heavy chain CDR1 represented by SEQ ID NO:7, heavy chain CDR2 represented by SEQ ID NO:8, heavy chain CDR3 represented by SEQ ID NO:9. Also disclosed is a method for the treatment and emergency prevention of diseases caused by various strains of the severe acute respiratory syndrome virus SARS-CoV-2 by the created agent.

EFFECT: inventions group provides for the creation of an effective agent with virus-neutralizing activity and protective activity against the SARS-CoV-2 virus, including variants that cause concern (Alpha, Beta, Gamma, Delta).

5 cl, 10 dwg, 13 tbl, 12 ex